Publications

        Search PubMed for all articles

  1. (2024) Abstract LB005: Identification of novel targets for MYC-driven hepatocellular carcinoma via transomics SP Fricker, CJ Nicholson, SJ Roth, A Singh, C Brown, J Hu, P Buiga, ... Cancer Research 84 (7_Supplement), LB005-LB005
  2. (2024) A big step for MYC-targeted therapies DF Atibalentja, A Deutzmann, DW Felsher Trends in Cancer 
  3. (2024) Development of a cancer-activated biologic imaging platform for early lung cancer diagnosis M Goryawala, HYH Lee, L Tong, T Patil, A Harwig, C Xia, ... Cancer Research 84 (6_Supplement), 4151-4151
  4. (2024) Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma A Deutzmann, DK Sullivan, R Dhanasekaran, W Li, X Chen, L Tong, ... Nature Communications 15 (1), 963
  5. (2023) Inhibitors of phospholipid synthesis and methods of use A Gouw, DW Felsher, F Jin, RN Zare, K Margulis, SR Schow, ... US Patent 11,702,394
  6. (2023) Single-nucleus chromatin accessibility identifies a critical role for TWIST1 in idiopathic pulmonary fibrosis myofibroblast activity E Valenzi, H Bahudhanapati, J Tan, T Tabib, DI Sullivan, M Nouraie, ... European Respiratory Journal 62 (1)
  7. (2023) Profiling and treatment of MYC-associated cancers with NK cells and type 1 interferon S Swaminathan, DW Felsher, HT Maecker US Patent 11,648,275
  8. (2023) Combined anti-cytokine therapy to reduce metastatic cancer V Baylot, R Dhanasekaran, DW Felsher US Patent App. 17/905,043
  9. (2023) Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells S Kuruvilla, DW Felsher, CK Lee US Patent App. 17/904,562
  10. (2023) MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint BAH Smith, A Deutzmann, KM Correa, CS Delaveris, R Dhanasekaran, ... Proceedings of the National Academy of Sciences 120 (11), e2215376120
  11. (2023) MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages R Dhanasekaran, AS Hansen, J Park, L Lemaitre, I Lai, N Adeniji, ... Cancer research 83 (4), 626-640
  12. (2023)Target genes in myc-driven neoplasia A Deutzmann, DW Felsher, Y Li US Patent 11,576,912
  13. (2023) Azapodophyllotoxin derivatives and methods of treating lymphoma and kidney cancer A Gouw, S Malhotra, DW Felsher US Patent App. 17/772,940
  14. (2023) Bi-steric mTORC1-selective inhibitors activate 4E-BP1, suppress MYC. Restore anti-tumor immunity, and co-operate with immune checkpoint inhibition to elicit tumor regression WD Mahauad-Fernandez, YC Yang, I Lai, J Park, L Yao, JW Evans, ... Cancer Res 83, LB015
  15. (2022) MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes DK Sullivan, A Deutzmann, J Yarbrough, MS Krishnan, AM Gouw, ... Oncogene 41 (45), 4960-4970
  16. (2022) Inhibitors of phospholipid synthesis and methods of use A Gouw, SR Schow, RJ Greenhouse, T Kline, DW Felsher US Patent App. 17/635,891
  17. (2022) Methods of Enhancing Immunogenicity of Cancers D Felsher, CR Bertozzi, A Deutzmann, B Smith, S Wisnovsky US Patent App. 17/625,264
  18. (2022) The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. Nat Rev Clin Oncol. 2021 Sep 10. doi: 10.1038/s41571-021-00549-2. Online ahead of print. PMID: 34508258
  19. (2022) Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells YY Gong, H Shao, Y Li, P Brafford, ZE Stine, J Sun, DW Felsher, ... Cancer research communications 2 (8), 842-856
  20. (2022) Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells L Tong, M Shan, W Zou, XL Liu, DW Felsher, J Wang Frontiers in Oncology 12, 904969
  21. (2022) A more sensitive approach to cancer imaging using cancer-activated PET reporters A Harwig, M Wang, L Tong, R Nieu, V Nguyen, D Felsher, D Suhy Cancer Research 82 (12_Supplement), 2480-2480
  22. (2022) Bi-steric mTORC1 inhibitor RMC-6272 synergizes with immune checkpoint inhibitors to induce sustained regression of MYC-driven hepatocellular carcinoma WD Mahauad-Fernandez, YC Yang, I Lai, J Park, L Yao, JW Evans, ... Cancer Research 82 (12_Supplement), 2662-2662
  23. (2022) MYC Overexpression Drives Immune Evasion in Human Cancer that is Reversible Through Restoration of Pro-Inflammatory Macrophages R Dhanasekaran, AS Hansen, J Park, I Lai, N Adeniji, S Kuruvilla, ... bioRxiv, 2022.05. 13.491873
  24. (2022) Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols AM Gouw, V Kumar, A Resendez, FB Alvina, NS Liu, K Margulis, L Tong, ... ACS Medicinal Chemistry Letters 13 (4), 615-622
  25. (2022) Anti-PD-L1 F (ab) conjugated PEG-PLGA nanoparticle enhances immune checkpoint therapy CK Lee, DF Atibalentja, LE Yao, J Park, S Kuruvilla, DW Felsher Nanotheranostics 6 (3), 243
  26. (2022) Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach L Lowe, JW LaValley, DW Felsher Cancer Drug Resistance 5 (4), 917
  27. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia. Mahauad-Fernandez WD, Rakhra K, Felsher DW. Methods Mol Biol. 2021;2318:297-312. doi: 10.1007/978-1-0716-1476-1_16. PMID: 34019298
  28. Twist1 is required for the development of UVB-induced squamous cell carcinoma. Eguiarte-Solomon F, Blazanin N, Rho O, Carbajal S, Felsher DW, Tran PT, DiGiovanni J. Mol Carcinog. 2021 May;60(5):342-353. doi: 10.1002/mc.23296. Epub 2021 Mar 13. PMID: 33713497
  29. Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging. Chen H, Shou K, Chen S, Qu C, Wang Z, Jiang L, Zhu M, Ding B, Qian K, Ji A, Lou H, Tong L, Hsu A, Wang Y, Felsher DW, Hu Z, Tian J, Cheng Z. Adv Mater. 2021 Apr;33(16):e2006902. doi: 10.1002/adma.202006902. Epub 2021 Mar 12. PMID: 33709533
  30. A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. Hori SS, Tong L, Swaminathan S, Liebersbach M, Wang J, Gambhir SS, Felsher DW. Sci Rep. 2021 Jan 14;11(1):1341. doi: 10.1038/s41598-020-78947-2. PMID: 33446671
  31. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Hepatology. 2021 Jun;73(6):2342-2360. doi: 10.1002/hep.31614. Epub 2021 May 8. PMID: 33140851
  32. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Cui L, Gouw AM, LaGory EL, Guo S, Attarwala N, Tang Y, Qi J, Chen YS, Gao Z, Casey KM, Bazhin AA, Chen M, Hu L, Xie J, Fang M, Zhang C, Zhu Q, Wang Z, Giaccia AJ, Gambhir SS, Zhu W, Felsher DW, Pegram MD, Goun EA, Le A, Rao J. Nat Biotechnol. 2021 Mar;39(3):357-367. doi: 10.1038/s41587-020-0707-9. Epub 2020 Oct 19. PMID: 33077961
  33. MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC. Dhanasekaran R, Park J, Yevtodiyenko A, Bellovin DI, Adam SJ, Kd AR, Gabay M, Fernando H, Arzeno J, Arjunan V, Gryanzov S, Felsher DW. Mol Ther Nucleic Acids. 2020 Sep 4;21:850-859. doi: 10.1016/j.omtn.2020.07.008. Epub 2020 Jul 10. PMID: 32805488
  34. The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship? Mahauad-Fernandez WD, Felsher DW. Cancer Res. 2020 Sep 15;80(18):3799-3802. doi: 10.1158/0008-5472.CAN-20-0787. Epub 2020 Jul 30. PMID: 32732221
  35. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Swaminathan S, Hansen AS, Heftdal LD, Dhanasekaran R, Deutzmann A, Fernandez WDM, Liefwalker DF, Horton C, Mosley A, Liebersbach M, Maecker HT, Felsher DW. Nat Commun. 2020 Jun 5;11(1):2860. doi: 10.1038/s41467-020-16447-7. PMID: 32503978
  36. The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them. Smith MT, Guyton KZ, Kleinstreuer N, Borrel A, Cardenas A, Chiu WA, Felsher DW, Gibbons CF, Goodson WH 3rd, Houck KA, Kane AB, La Merrill MA, Lebrec H, Lowe L, McHale CM, Minocherhomji S, Rieswijk L, Sandy MS, Sone H, Wang A, Zhang L, Zeise L, Fielden M. Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1887-1903. doi: 10.1158/1055-9965.EPI-19-1346. Epub 2020 Mar 9. PMID: 32152214
  37. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Rajan Kd A, Lai I, Gabay M, Tong L, Krishnan M, Park J, Hu T, Barbhuiya MA, Gentles AJ, Kannan K, Tran PT, Felsher DW. Elife. 2020 Jan 14;9:e50731. doi: 10.7554/eLife.50731. PMID: 31933479
  38. Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Li Y, Thomas D, Deutzmann A, Majeti R, Felsher DW, Dill DL. Sci Rep. 2019 Nov 14;9(1):16775. doi: 10.1038/s41598-019-53290-3. PMID: 31727951
  39. Gouw AM, Margulis K, Liu NS, Raman SJ, Mancuso A, Toal GG, Tong L, Mosley A, Hsieh AL, Sullivan DK, Stine ZE, Altman BJ, Schulze A, Dang CV, Zare RN, Felsher DW. Cell Metab. 2019 Sep 3;30(3):556-572.e5. doi: 10.1016/j.cmet.2019.07.012. Epub 2019 Aug 22. PMID: 31447321
  40. Lipid nanoparticles that deliver IL-12 messenge RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma (accepted Journal for ImmunoTherapy of Cancer)
  41. Dhanasekaran R, Gabay-Ryan M, Baylot V, Lai I, Mosley A, Huang X, Zabludoff S, Li J, Kaimal V, Karmali P, Felsher DW. Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget. 2017: 9:5517-5528. PMID: 29464015
  42. Hebb JPO, Mosley AR, Vences-Catalán F, Rajasekaran N, Rosén A, Ellmark P, Felsher DW. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunol Immunother. 2017 Sep 13. doi: 10.1007/s00262-017-2059-y. [Epub ahead of print] PMID: 28905118
  43. Gouw AM, Eberlin LS, Margulis K, Sullivan DK, Toal GG, Tong L, Zare RN, Felsher DW.
    Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4300-4305. doi: 10.1073/pnas.1617709114. Epub 2017 Apr 11. PMID: 28400509
  44. Casey SC, Baylot V, Felsher DW. Trends Immunol. 2017 Apr;38(4):298-305. doi: 10.1016/j.it.2017.01.002. PMID: 28233639
  45. Li Y, Deutzmann A, Felsher DW. BIM-mediated apoptosis and oncogene addiction.  Aging (Albany NY). 2016 Sep 29;8(9):1834-1835. doi: 10.18632/aging.101072. PubMed PMID: 27688082.
  46. Felsher DW, Lowe L. Affordable Cancer Medications Are Within Reach but We Need a Different Approach. J Clin Oncol. 2016 Jun 20;34(18):2194-5. doi: 10.1200/JCO.2016.67.2436. PubMed PMID: 27161965.
  47. Li Y, Deutzmann A, Choi PS, Fan AC, Felsher DW. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. Oncotarget. 2016 May 10;7(19):26926-34. doi: 10.18632/oncotarget.8731. PubMed PMID: 27095570.
  48. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. PubMed PMID: 26966191; PubMed Central PMCID: PMC4940030.
  49. Gouw AM, Toal GG, Felsher DW. Metabolic vulnerabilities of MYC-induced cancer. Oncotarget. 2016 May 24;7(21):29879-80. doi: 10.18632/oncotarget.7223. PubMed PMID: 26863454.
  50. Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, van Riggelen J, Plevritis S, Felsher DW. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget. 2015 Feb 28;6(6):3563-77. PubMed PMID: 25784651; PubMed Central PMCID: PMC4414137.
  51. Li Y, Choi PS, Felsher DW. Oncogene addiction: resetting the safety switch? Oncotarget. 2014 Sep 30;5(18):7986-7. PubMed PMID: 25275297; PubMed Central PMCID: PMC4226662.
  52. Li Y, Casey SC, Choi PS, Felsher DW. miR-17-92 explains MYC oncogene addiction. Mol Cell Oncol. 2014 Dec 31;1(4):e970092. doi: 10.4161/23723548.2014.970092. PubMed PMID: 27308380; PubMed Central PMCID: PMC4905255.
  53. Li Y, Choi PS, Felsher DW. Oncogene addiction: resetting the safety switch? Oncotarget. 2014 Sep 20. [Epub ahead of print] PubMed PMID: 25275297.
  54. Li Y, Choi PS, Casey SC, Felsher DW. Activation of cre recombinase alone can induce complete tumor regression. PLoS One. 2014 Sep 10;9(9):e107589. doi: 10.1371/journal.pone.0107589. eCollection 2014. PubMed PMID: 25208064; PubMed Central PMCID: PMC4160265.
  55. Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell. 2014 Aug 11;26(2):262-72. doi: 10.1016/j.ccr.2014.06.014. PubMed PMID: 25117713.
  56. Casey SC, Li Y, Fan AC, Felsher DW. Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer. 2014 Jul 15;2:24. doi: 10.1186/2051-1426-2-24. eCollection 2014. Review. PubMed PMID: 25089198; PubMed Central PMCID: PMC4118610.
  57. Choi PS, Li Y, Felsher DW. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3316-24. doi: 10.1073/pnas.1406123111. Epub 2014 Jul 28. PubMed PMID: 25071175; PubMed Central PMCID: PMC4136575.
  58. Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN. Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc  Natl Acad Sci U S A. 2014 Jul 22;111(29):10450-5. doi: 10.1073/pnas.1409778111. Epub 2014 Jul 3. PubMed PMID: 24994904; PubMed Central PMCID: PMC4115527.
  59. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a014241. doi: 10.1101/cshperspect.a014241. PubMed PMID: 24890832.
  60. Ye D, Shuhendler AJ, Cui L, Tong L, Tee SS, Tikhomirov G, Felsher DW, Rao J. Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat Chem. 2014 Jun;6(6):519-26. doi: 10.1038/nchem.1920. Epub 2014 Apr 28. PubMed PMID: 24848238; PubMed Central PMCID: PMC4031611.
  61. Casey SC, Li Y, Felsher DW. An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res. 2014 May;58(2-3):282-91. doi: 10.1007/s12026-014-8503-6. PubMed PMID: 24791942.
  62. Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis. J Intern Med. 2014 Jul;276(1):52-60. doi: 10.1111/joim.12237. Review. PubMed PMID:  24645771; PubMed Central PMCID: PMC4065197.
  63. Cao Z, Ding BS, Guo P, Lee SB, Butler JM, Casey SC, Simons M, Tam W, Felsher  DW, Shido K, Rafii A, Scandura JM, Rafii S. Angiocrine factors deployed by tumor  vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell. 2014 Mar 17;25(3):350-65. doi: 10.1016/j.ccr.2014.02.005. PubMed PMID: 24651014; PubMed Central PMCID: PMC4017921.
  64. Nwabugwu CI, Rakhra K, Felsher DW, Paik DS. A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:4529-32. doi: 10.1109/EMBC.2013.6610554. PubMed PMID: 24110741.
  65. Rakhra K, Felsher DW. Generation of a tetracycline regulated mouse model of MYC-induced T-cell acute lymphoblastic leukemia. Methods Mol Biol. 2013;1012:221-35. doi: 10.1007/978-1-62703-429-6_15. PubMed PMID: 24006068.
  66. Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, Castaneda R, Hazard FK, Tong L, Lenkov OD, Felsher DW, Rao J, Daldrup-Link HE. Development  of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small. 2014 Feb 12;10(3):566-75, 417. doi: 10.1002/smll.201301456. Epub  2013 Aug 27. PubMed PMID: 24038954; PubMed Central PMCID: PMC3946335.
  67. Fan AC, O'Rourke JJ, Praharaj DR, Felsher DW. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs. 2013 Nov;22(11):1495-509. doi: 10.1517/13543784.2013.829453. Epub 2013 Aug 12. Review. PubMed PMID: 23937225; PubMed Central PMCID: PMC4111569.
  68. Casey SC, Bellovin DI, Felsher DW. Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol. 2013 Apr;25(2):246-58. doi: 10.1016/j.coi.2013.02.003. Epub 2013 Apr 6. Review. PubMed PMID: 23571026; PubMed Central PMCID: PMC3683588.

        Search PubMed for all articles